RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Agenti Attivi sul Sistema Nervoso Centrale: Moderni Approcci Chimico-Farmaceutici per la Modulazione e Caratterizzazione di Pathways Recettoriali
• 2 - Progettazione e sintesi di ligandi recettoriali/enzimatici per lo sviluppo di farmaci ad azione antiischemica/neuroprotettiva e modulatoria del sistema nervoso centrale
• 3 - Progettazione, sintesi e valutazioni bio-farmacologiche preliminari di ligandi utili allo sviluppo di farmaci per le patologie neurodegenerative del S.N.C. - Un approccio multirecettoriale.
• 4 - Polipeptidi Bioattivi e Nanostrutturati: Struttura Molecolare e Supramolecolare, Attività Biologica, Sintesi Innovative.
• 5 - Nuovi ligandi e modulatori per la caratterizzazione dei neurorecettori e per il trattamento delle relative disfunzioni
• 6 - SINTESI E CARATTERIZZAZIONE FARMACOLOGICA DI NUOVE MOLECOLE SELETTIVE PER IL RECETTORE BENZODIAZEPINICO PERIFERICO UTILI PER LA MODULAZIONE DELLA NEUROSTEROIDOGENESI, PER LA DIAGNOSI DI MALATTIE NEURODEGENERATIVE E PER IL DIREZIONAMENTO DI FARMACI ANTITUMORALI
• 7 - Sintesi e applicazioni di ligandi delle integrine e loro coniugati
• 8 - Progettazione, sintesi e attività biologica di inibitori di metalloenzimi coinvolti nelle patologie neurodegenerative, infiammatorie e tumorali.
• 9 - I sistemi recettoriali dei neurotrasmettitori: progettazione e sintesi di molecole utili per la loro caratterizzazione e modulazione e per il trattamento delle relative disfunzioni
• 10 - Neurotrasmissione glutamatergica: organizzazione strutturale della sinapsi, recettori e ruolo in fisiopatologia."

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA FARMACEUTICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • HETEROCYCLIC COMPOUNDS
    • SUGARS; DERIVATIVES THEREOF (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C121/36; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; sugar and starch industry C13)

Classificazione geografica

• Regione: Umbria

Bibliografia

1. Aarts MM, Tymianski M. Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors. Biochem Pharmacol. 2003 Sep 15;66(6):877-86.
2. Bräuner-Osborne, H.; Egebjerg, J.; Nielsen, E. Ø.; Madsen, U.; Krogsgaard-Larsen, P. Ligands for Glutamate Receptors: Design and Therapeutic Prospects. J. Med. Chem. 2000, 43, 2609-2645
3. Costantino G, Macchiarulo A, Pellicciari R. Metabotropic glutamate receptors: targets for therapy of cerebral ischaemia. Expert Opin Ther Targets. 2001 Dec;5(6):669-683
4. Conn PJ. Physiological roles and therapeutic potential of metabotropic glutamate receptors.
Ann N Y Acad Sci. 2003 Nov;1003:12-21
5. Lipton SA, NMDA Receptors, Glial Cells, and Clinical Medicine. Neuron, 2006 Apr 6;50(1):9-11.
6. Shi, Q.,Savage, J. E.,Hufeisen, S. J.,Rauser, L.,Grajkowska, E. et al. L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J Pharmacol Exp Ther, 2003, 305, 131-142.
7. Gitto R, Barreca ML, De Sarro G, Quartarone S, Orlando V, De Luca L, Russo E, Chimirri A. (2003) Discovery of a new class of AMPA receptor antagonists containing a tetrahydroisoquinoline skeleton. Drugs of the Future. vol. 27 (Suppl. A), 252
8. Barreca ML, Gitto R, Quartarone S, De Luca L, De Sarro G, Chimirri A. "Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists". J Chem Inf Comput Sci, 43 (2), 651-655 (2003)
9. Gitto R.;. Barreca M. L.; De Luca L.; De Sarro G.; Ferreri G.; Quartarone S.; Russo E.; Constanti A.; Chimirri A. (2003)Discovery of a Novel and Highly Potent Noncompetitive AMPA Receptor Antagonist J. Med. Chem., 46, 197-200
10. Gitto R, Barreca ML, Francica E, Caruso R, De Luca L, De Sarro G, Chimirri A. "Synthesis and anticonvulsant properties of 1,2,3,4-tetrahydroisoquinolin-1-ones". Arkivoc, Part(v) 170-180 (2004)
11. Ferreri G, Chimirri A, Russo E, Gitto R, Gareri P, De Sarro A, De Sarro G. "Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy- 1,2,3,4-tetrahydroisoquinoline derivatives in rodents". Pharmacol Biochem Behav, 77 (1), 85-94 (2004)
12. Gitto R, Caruso R, Orlando V, Barreca ML, Ferreri G, Russo E, De Sarro G, Chimirri A. "Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives". Farmaco, 59 (1), 7-12 (2004)
13. Ribeiro J.A. Curr. Drug. Targets CNS Neurol. Disord. 2005, 4, 325-329.
14. Stone, T.W. Adv Exp Med Biol. 2002, 513, 249-280.
15. Fredholm, B.B. Int. Rev. Neurobiol. 1997, 40, 259-280.
16. Golembiowska K. Neuropharmacology. 2000, 39, 2124-2132
17. Battacharaya S. et al. Biochim. Biophys. Acta 1995, 1265, 15-21
18. Maemoto T., Tada M., Mihara T., Ueyama N., Matsuoka H., Harada K., Yamaji T., Shirakawa K., Kuroda S., Akahane A., Iwashita A., Matsuoka N., Mutoh S. Pharmacological Characterization of FR194921, a New Potent, Selective,and Orally Active Antagonist for Central Adenosine A1 Receptors, J. Pharmacol. Sci. 2004, 96, 42–52.
19. Prediger R. D., Batista L. C., Takahashi R. N. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiol. Aging 2005, 26, 957-64.
20. Prediger R. D., Takahashi R. N. Modulation of short-term social memory in rats by adenosine A1 and A2A receptors. Neurosci. Lett. 2005, 376, 160-5.
21. Pereira G. S., Mello E., Souza T., Vinade E. R., Choi H., Rodrigues C., Battastini A. M., Izquierdo I., Sarkis J. J., Bonan C. D. Blockade of adenosine A1 receptors in the posterior cingulate cortex facilitates memory in rats. Eur. J. Pharmacol. 2002, 437, 151-4.
22. Volpini et al. Curr. Top. Med. Chem, 2003, 3, 427-443.
23. Ciccarelli R. et al. J. Neurosi. Res. 1994, 39, 556-566.
24. Piomelli D. The molecular logic of endocannabinoid signalling Nat Rev Neurosci. 2003; 4(11):873-84.
25. Van der Stelt M, Hansen HH, Veldhuis WB, Bar PR, Nicolay K, Veldink GA, Vliegenthart JF, Hansen HS. Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases. Neurotox Res. 2003;5(3):183-200.
26. Bahr BA, Karanian DA, Makanji SS, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs. 2006 Apr;15(4):351-65.
27. Kathuria S., Gaetani S., Fegley D., Duranti A., Tontini A., Mor M., La Rana G., Calignano A., Giustino A., Tattoli M., Cuomo V., Tarzia G., Piomelli D.; Modulation of anxiety through blockade of anandamide hydrolysis; Nat. Med., 9(1), 76-81; 2003.
28. Hohmann A.G., Suplita R.L., Bolton N.M., Neely M.H., Fegley D., Mangieri R., Krey J., Walker J. M., Holmes P. V., Crystal J. D., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D.; An endocannabinoid mechanism for stress-induced analgesia; Nature, 435, 1108-1112; 2005.
29. Howlett A. C., Barth F., Bonner T. I., Cabral G., Casellas P., Devane W. A., Felder C. C., Herkenham M., Mackie K., Martin B. R., Mechoulam R.; Pertwee R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 161-202.
30. Castellano C., Rossi-Arnaud C., Cestari V., Costanzi M. Cannabinoids and memory: animal studies. Curr. Drug Targets CNS Neurol. Disord. 2003, 2, 389-402 and literature cited therein.
31. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 1998, 5, 534-551.
32. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002 Oct;303(1):1-10.
33. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 2001, 64, 365-391.
34. Dudkowska M., Lai J., Gardini G., Stachurska A., Grzelakowska-Sztabert B., Colombato S., Maneuffel-Lymborowska M. Agmatine modulates the in vivo biosynthesis and interconversion of polyamines and cell proliferation. Biochim. Biophys. Acta 2003, 1619, 159-166.
35. Paul V., Reddy L., Ekambaram P. Related Articles, A reversal by L-arginine and sodium nitroprusside of ageing-induced memory impairment in rats by increasing nitric oxide concentration in the hippocampus. Indian J. Physiol. Pharmacol. 2005, 49, 179-186.
36. Hardy, J.; Selkoe, D. J. Science 2002, 297, 353-356
37. Grossberg, G.T. Int. Psychogeriatr. 2002, 14 (Suppl. 1), 27-49
38. Michaelis, M.L. J. Pharmacol. Exp. Ther. 2003, 304, 897-9041
39. Frei, B. “Natural antioxidants in human health and diseases”, Acad. Press, 1994.
40. Kontogiorgis, C. A.; Savvoglou, K.; Hadjipavlou-Litina D. J. J. Enzyme Inhib. Med. Chem. 2006, 21, 21 and references therein.
41. Catto, M.; Cellamare, S.; Chiti, F.; Carotti, A. Proceedings of EMBO-FEBS Workshop on Amyloid Formation (# 054), Florence 2006.
42. Morphy, R.; Kay, C.; Rankovic, Z. Drug Discov. Today 2004, 9, 641.
43. Morphy, R.; Rankovic, Z. J. Med. Chem. 2005, 48, 6523.
44. Catto, M.; Nicolotti, O.; Favia, A. D.; Leonetti, F.; Soto-Otero, R.; Méndez-Álvarez, E.; Carotti, A. J. Med. Chem. 2006, in press, and references therein.

Parole Chiave

SISTEMA NERVOSO CENTRALE, NEUROPROTEZIONE, MODELLISTICA MOLECOLARE, SINTESI INNOVATIVA, RECETTORI ED ENZIMI, MODULATORI, MALATTIE NEURODEGENERATIVE, PSICOSI